Jaguar Animal Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. on June 4, 2015, reporting events that occurred on June 2, 2015. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from four to five members.
- New Appointment: Folkert W. Kamphuis was appointed as a Class III Director, serving until the 2018 annual meeting.
- Committee Assignments: Mr. Kamphuis was appointed to the Compensation Committee and Nominating Committee, replacing Dr. Yang and Mr. Qiu, respectively.
- Committee Composition:
- Audit Committee: Messrs. Bochnowski and Qiu and Dr. Yang.
- Compensation Committee: Messrs. Bochnowski and Kamphuis.
- Nominating Committee: Messrs. Bochnowski and Kamphuis.
Compensatory Arrangements
In connection with the appointment, the Board granted stock options to non-employee directors under the 2014 Stock Incentive Plan. All options have an exercise price of $6.70 per share, vest monthly over 3 years, and expire 10 years from the grant date.
| Director | Options Granted |
|---|---|
| Mr. Bochnowski | 20,000 |
| Mr. Kamphuis | 50,000 |
| Mr. Qiu | 10,000 |
| Dr. Yang | 10,000 |
Management Commentary and Background
The Board cited Mr. Kamphuis's extensive experience in the animal health sector as the basis for his appointment. His background includes serving as Global Head of Strategic Planning at Novartis Animal Health (until its acquisition by Elanco), General Manager North America, and Chief Operating Officer. He previously held executive roles at Pfizer Animal Health and Merial/Merck Sharp & Dohme.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price ($6.70) of the new director options.
- Confirm the updated composition of the Audit, Compensation, and Nominating committees.
- Review the press release filed as Exhibit 99.1 for additional details on the appointment.
- Check subsequent filings for any changes to the Board composition or committee assignments.